Improved discrimination of AD patients using β-amyloid <sub>(1-42)</sub> and tau levels in CSF

1999732 citationsJournal Articlegreen Open Access

Authors

Frank Hulstaert · ZNA Middelheim Hospital

Kaj Blennow · ZNA Middelheim Hospital

Adrian Ivanoiu · ZNA Middelheim Hospital

H.C. Schoonderwaldt · ZNA Middelheim Hospital

Markus J. Riemenschneider · ZNA Middelheim Hospital

P.P. De Deyn · ZNA Middelheim Hospital

C. Bancher ·

Abstract

The combined measure of CSF Abeta42 and tau meets the requirements for clinical use in discriminating AD from normal aging and specific neurologic disorders.

Topics & Keywords

Alzheimer's disease research and treatments Dementia and Cognitive Impairment Research Neurological Disorders and Treatments

UN Sustainable Development Goals

Reduced inequalities

Publication Details

Published in: Neurology

Volume 52, Issue 8, pp. 1555-1555

DOI: 10.1212/wnl.52.8.1555

Field-Weighted Citation Impact: 14.56